Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Gut response. Therapy with ingested immunomodulatory proteins. Arch Neurol 1997 Oct;54(10):1300-2

Date

10/28/1997

Pubmed ID

9341578

DOI

10.1001/archneur.1997.00550220098021

Scopus ID

2-s2.0-0030824070   12 Citations

Abstract

The recent negative results of the 2-year phase III trial of enteral myelin (Myloral), a preparation of bovine myelin given orally in multiple sclerosis (MS), warn that the efficacy of oral tolerization (ie, inducing hyporesponsiveness to a specific autoantigen) and the attractiveness of oral desensitization in animal models of MS may not translate into clinical practice. However, such failure should not deter further examination of the mouth, an immunologically interesting and patient-friendly route for immunomodulatory proteins.

Author List

Brod SA

Author

Staley A. Brod MD Professor in the Neurology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adjuvants, Immunologic
Administration, Oral
Animals
Cattle
Clinical Trials as Topic
Humans
Immunotherapy
Multiple Sclerosis
Myelin Sheath
Nerve Tissue Proteins
Treatment Failure